E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy volunteers (Prevention of RSV LRTI in infants) |
|
E.1.1.1 | Medical condition in easily understood language |
Respiratory syncytial virus (RSV) is a common virus that leads to cold-like symptoms in adults and healthy children. RSV can cause more serious disease in infants, such as inflammation of the lungs. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10035692 |
E.1.2 | Term | Pneumonia due to respiratory syncytial virus |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038718 |
E.1.2 | Term | Respiratory syncytial virus bronchiolitis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066741 |
E.1.2 | Term | Respiratory syncytial virus infection recurrent |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061603 |
E.1.2 | Term | Respiratory syncytial virus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052200 |
E.1.2 | Term | Respiratory syncytial virus infection NOS |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067384 |
E.1.2 | Term | Respiratory syncytial virus pneumonitis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and reactogenicity of three dose levels (30, 60, 120 µg) of the RSV maternal investigational vaccine administered as a single intramuscular injection, as compared to placebo up to 1month post vaccination (Day 31). |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety of three dose levels (30, 60, 120 µg) of the RSV maternal investigational vaccine compared to placebo up to 6 months post vaccination (Day 181).
To evaluate the humoral immune response to three dose levels (30, 60, 120 µg) of the RSV maternal investigational vaccine compared to placebo up to 3 months post vaccination (Day 91).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects who the investigator believes will comply with the requirements of the protocol (e.g. completion of the diary cards/questionnaires, return for follow-up visits, have regular contact to allow evaluation during the study);
• Written informed consent obtained from the subject;
• Healthy female subjects; as established by medical history and clinical examination, aged 18 to 45 years at the time of the vaccination;
• Female subjects of childbearing potential may be enrolled in the study, if the subject:
has practiced adequate contraception for 30 days prior to vaccination, and
has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception until 90 days after vaccination
|
|
E.4 | Principal exclusion criteria |
•Use of any investigational or non-registered product other than the study vaccine within 30 days preceding vaccination or any planned use during the study period;
•Concurrently participating in the active phase of another clinical study, at any time during the study period, in which the subject has been or will be exposed to an in-vestigational or a non-investigational vaccine/product
•Chronic administration (defined as more than 14 days in total) of immunosuppressant or other immune-modifying drugs, as well as administration of long acting immune modifying drugs, within 6 months prior to the vaccine dose (for corticosteroids, this will mean prednisone higher than or equal to (≥) 5 milligrams per day (mg/day), or equivalent). Inhaled and topical steroids are allowed;
•Administration or planned administration of immunoglobulins and/or any blood products during the period starting 3 months before or 3 months after
•Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after study vaccination, with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before or after study vaccination;
•Previous experimental vaccination against RSV;
•Presence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports;
•Family history of congenital or hereditary immunodeficiency;
•Any confirmed or suspected immunosuppressive or immunodeficient condition;
•History of allergic disease or reactions likely to be exacerbated by any component of the vaccine;
•Any acute or chronic, clinically significant disease
The following conditions will be exclusionary:
Diabetes mellitus,
Respiratory diseases, such as:
oChronic Pulmonary diseases, including Chronic Obstructive Pulmonary Disease (COPD),
oBronchopulmonary dysplasia (note: history of past bronchopulmonary dysplasia as a neonate/infant will not be exclusionary),
oUncontrolled asthma or asthma necessitating treatment with chronic systemic glucocorticoids
Significant and/or uncontrolled psychiatric illness:
ohospitalization for psychiatric illness, history of suicide attempt(s) or confinement for danger to self or others within 10 years
oclinically significant depression
Major neurological disease including:
oseizure or adulthood epilepsy
omyasthenia gravis
ohistory of repetitive migraine mal/status mi-grainosus
Significant cardiovascular disease, including:
oUncontrolled arterial hypertension,
oCongenital heart disease (with the exception of corrected atrial or ventricular septal defects),
oPrevious myocardial infarction,
oValvular heart disease or history of rheumatic fever,
oPrevious bacterial endocarditis,
oHistory of cardiac surgery (with the exception of corrected atrial or ventricular septal defects),
oPersonal or family history of cardiomyopathy or sudden adult death.
Known or suspected Hepatitis B or Hepatitis C infection,
Any other significant uncontrolled medical illness, defined as any illness requiring new medical and/or surgical treatment or significant modification of treatment dose due to uncontrolled symptoms or drug toxicity, within 3 months prior to study vaccination.
•History of or current autoimmune disease;
•Body mass index (BMI) > 40 Kilograms (kg)/square meters(m^2);
•Pregnant or lactating female;
•Female planning to become pregnant or planning to discontinue contraceptive precautions;
•Hypersensitivity to latex;
•Lymphoproliferative disorder or malignancy within previous 5 years;
•Acute disease and/or fever at the time of enrolment;
Subjects with fever at screening may be re-screened 1 time at a later date.
Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
•Any clinically significant or any ≥ Grade 2* haematological (haemoglobin level, white blood cell, lymphocyte, neutrophil, eosinophil, and platelets) and biochemical (alanine aminotransferase [ALT] aspartate aminotrans-ferase [AST], creatinine, blood urea nitrogen [BUN]) la-boratory abnormality detected at the last screening blood sampling;
For Grade 1 laboratory abnormalities, the investigator should use clinical judgement to decide which ones are clinically relevant.
Subjects with haematological/biochemical values out of normal range at screening which are expected to be temporary, may be re-screened 1 time at a later date.
•Any other condition that the investigator judges may interfere with study procedures or findings;
•Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe;
•Alcoholism, drug abuse and/or use disorder within the past two years;
•Planned move to a location that will prohibit participating in the trial until study end.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of subjects with any solicited local adverse events (AE)
Number of subjects with any solicited local adverse events (AE)
Number of subjects with any unsolicited AEs
Number of subjects with serious adverse events (SAEs)
Number of subjects presenting haematological laboratory abnormalities.
Number of subjects presenting haematological laboratory abnormalities.
Number of subjects presenting biochemical laboratory abnor-malities
Number of subjects presenting biochemical laboratory abnor-malities
Number of subjects presenting biochemical laboratory abnor-malities, by maximum grading
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During a 7-day follow-up period (i.e., on the day of vaccination and 6 subsequent days).
During a 7-day follow-up period (i.e., on the day of vaccination and 6 subsequent days).
During a 30-day follow-up period after vaccination (i.e., on the day of vaccination and 29 subsequent days).
From Day 1 (vaccination) up to Day 30 (i.e., on the day of vaccination and 29 subsequent days).
At Day 8.
At Day 31
At Day 8
At Day 31
From baseline to Day 31
From Baseline to Day 31 |
|
E.5.2 | Secondary end point(s) |
Number of subjects with SAEs
Neutralizing antibody (Nab) titers against RSV serotype A.
Anti-Respiratory Syncytial Virus Prefusion 3 (RSVPreF3) Immunoglobulin G (IgG) antibody concentrations. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From Day 1 (vaccination) up to Day 91 and up to Day 181
At pre-vaccination (Screening visit), 7 days post vaccination (Day 8), 30 days post vaccination (Day 31), 60 days post vaccination (Day 61) and 90 days post vaccination (Day 91)
At pre-vaccination (Screening visit), 7 days post vaccination (Day 8), 30 days post vaccination (Day 31), 60 days post vaccination (Day 61) and 90 days post vaccination (Day 91) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 9 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Finland |
Germany |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last testing results released for samples collected at Visit 5 (Day 91) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |